DOCSLIB.ORG

Single Or Combination Treatment of Serious S. Aureus Infections

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Single Or Combination Treatment of Serious S. Aureus Infections Single or combinationBildbereich treatment of seriousBitte auf der S. Masterfolie aureus austauschen infections Siegbert Rieg Division of Infectious Diseases, Department of Medicine II & Center of Chronic Immunodeficiency (CCI) ESCMIDUniversity Medical eLibrary Center Freiburg, Germany © by author S. aureus – spectrum of serious infections osteoarticular infections & PJI complicated SSTI endocarditis deep-seated manifestations ESCMID eLibrary © by author (n=1493) community-acquired SAB healthcare-associated SAB 150 nosocomial SAB 100 50 SAB cases per year cases SAB 0 ESCMID2006 2007 2008eLibrary2009 2010 2011 2013 2014 2015 University Medical Center Freiburg Ingram,© Clinby Microbiol Infectauthor 2014 rationale for co-therapy in general synergistic effects (at least in vitro) bactericidal activity diminish potential resistance development S. aureus – specific reasons targeting intracellular reservoir effects on biofilm / devices decrease toxin production treatment of small colony variants preventESCMIDdissemination eLibrary © by author case #1 – 19yo male with bicuspid aortic valve History healthy student, 4 days prior to admission fever and chills no IVDA, no travel abroad, no other specific risk factors Clinical findings emergency department petechial lesions on palmes and soles, slight neck stiffness mental status changes Lab WBC 5000/µl, CRP 340 mg/L (<5mg/L), procalcitonin 52 ng/mL (<0.5 ng/mL), creatinin 2.1 mg/dL Cerebral CT scan on admission Subacute cerebellar ischemic lesion Blood cultures on admission S. aureus Oxa S Admission to neurology Lumbar puncture WBC 350/µl (95% PMNs), protein 0.64 g/L, S. aureus Oxa S TEE bicuspic aortic valve, 16 mm vegetation and grade III regurgitation ESCMID eLibrary © by author case #1 – 19yo male with bicuspid aortic valve Patient was initially treated with ceftriaxon, ampicillin and aciclovir What treatment would you recommend now? 1. Continue ceftriaxon and ampicillin 2. Switch to flucloxacillin adjusted to renal function 6g/d 3. Switch to flucloxacillin 8-12g/d 4. Switch to flucloxacillin 8-12g/d plus gentamicin 3 x 60 mg/d 5. Switch to flucloxacillin 8-12g/d plus rifampicin 2 x 450 mg/d ESCMID eLibrary © by author ESC and AHA endocarditis guidelines Staphylococcal native valve endocarditis ESCMID eLibrary Habib, Eur Heart© Journal by 2015 | Baddourauthor, Circulation 2015 co-therapy – in vitro evidence or ‚choosing the right model‘… susceptibility testing checkerboard test, time-kill studies, disc diffusion, E-test synergistic vs. additive effect vs. indifference vs. anatgonism rifampicin plus antistaph penicillins, cephalosporins synergy at subinhibitory rifa concentrations vs. indifference or anatagonism at higher concentrations vancomycin - antagonisitic or indifferent fluoroquinolones - synergy only at subinhibitory rifa concentrations linezolid - mostly additive effects noted animal models ESCMIDmouse vs. rat vs. rabbit endocarditis eLibrarymodel animal survival, sterilisation of vegetations vs. secondary foci Forrest , J Clin Microbiol 2010© | Nguyen by, JAC 2010 author | Perlroth, Arch Intern Med 2008 co-therapy in native valve endocarditis retrospect cohort analysis, 84 cases of native valve endocarditis standard vs. standard & rifampin co-therapy associated with longer bacteremia duration higher mortality and relapse drug interactions RCT of 42 patients MRSA endocarditis vanco mono vs. vanco & rifampin median duration bacteremia 9 vs. 7 days no significant difference in mortality native valve endocarditis – high inoculum infection, with biofilm formation ESCMIDand reduced susceptibility eLibrarywithin vegetation Riedel, ©AAC 2008 by | Levine, Annauthor Intern Med 1991 Survey on endocarditis treatment practices in large referral centers ESCMID eLibrary Tissot -Dupont,© ClinbyMicrobiol authorInfect 2017 (in press) case #1 – 19yo male with bicuspid aortic valve …complicated and fatal courseCT 18.12. MR 21.12. MR scan . embolisation with stroke & secondary hemorrhage . prolonged positive blood cultures (until day 9) . perivalvular abscess with perforation . progressive heart failure . patient died 12 days after presentation TEE 29.12. CT scan ESCMID eLibrary © by author case #2 – 79yo male with community-acquired SAB History metabolic syndrom with coronary artery disese, pain inguinal region/lower abdomen for 7 days, general malaise, episode of chills 5 days ago clinical findings emergency department slight pain on palpation symphysis pubis region, no other pertinent findings Lab WBC 13.000/µl, CRP 170 mg/L (<5mg/L), procalcitonin 0.9 ng/mL (<0.5 ng/mL) Pelvic CT scan slight edema in symphysis region Blood cultures on admission S. aureus Oxa S TTE & TEE no vegetations or other signs of endocarditis ESCMID eLibrary © by author case #2 – 79yo male with community-acquired SAB After having received blood culture results (MSSA), which treatment would you initiate? 1. Flucloxacillin 8g/d 2. Cefazolin 6g/d 3. Flucloxacillin 8g/24h plus rifampicin 900mg/d 4. Flucloxacillin 8g/24h plus fosfomycin 12g/d 5. Flucloxacillin 8g/24h plus levofloxacin 750mg/d ESCMID eLibrary © by author case #2 – 79yo male with community-acquired SAB History metabolic syndrom with coronary artery disese pain inguinal region/lower abdomen for 7 days, general malaise, episode of chills 5 days ago clinical findings emergency department slight pain on palpation symphysis pubis region, no other pertinent findings Lab WBC 13.000/µl, CRP 170 mg/L (<5mg/L), procalcitonin 0.9 ng/mL (<0.5 ng/mL) Pelvic CT scan slight edema in symphysis region Blood cultures on admission S. aureus Oxa S TTE & TEE no vegetations or other signs of endocarditis Bone scan and MRI symphysitis pubis …and we notice a pacemaker is in situ ESCMID eLibrary © by author case #2 – 79yo male with community-acquired SAB Knowing about the implanted foreign body/device, would you change the antibiotic regimen? 1. No, continue Flucloxacillin 8g/d 2. No, continue Cefazolin 6g/d 3. Add rifampicin 900mg/d 4. Add fosfomycin 12g/d 5. Add levofloxacin 750mg/d ESCMID eLibrary © by author co-therapy in S. aureus bacteremia comparative studies until 2011 ESCMID eLibrary ©Thwaites by, Lancet Infect authorDis 2011 co-therapy in S. aureus bacteremia comparative studies until 2011 ESCMID eLibrary Ruotsalainen ©, J Intern Medby2006 | Thwaitesauthor, Trials 2012 co-therapy in S. aureus bacteremia newer studies 357 patients surviving for at least 3 days primary endpoint day 90-mortality ESCMID eLibrary ©Forsblom by, PLoS One author2014 co-therapy in S. aureus bacteremia newer studies INSTINCT-cohort, post hoc-analysis (n=964) Monotherapy Combination therapy (MoRx) (CoRx) Cell-wall active agent MoRx plus rifampicin, (β-lactam, fluoroquinolone, vancomycin, fosfomycin or daptomycin) gentamicin a djustmentESCMIDfor survivor eLibrarybias ©Rieg, ClinbyMicrobiol Infectauthor2016 All patients (n=964), endpoint day 90-mortality Combination therapy (ref: no) 0.661 0.510 0.856 0.0017 withoutESCMIDadjustment for survivor eLibrarybias! ©Rieg, ClinbyMicrobiol Infectauthor2016 co-therapy in S. aureus bacteremia newer studies Subgroup analysis – day 90-mortality unchanged in com-acqu. SAB, disseminated SAB, severe sepsis/shock implanted foreign bodies/devices (n=344) HR 0.61 [CI 0.40-0.92] [prosth. heart valve, PM/ICD, vascular grafts, orthoped. prosthesis in situ] only rifampicin co-therapy (n=266) HR 0.55 [CI 0.33-0.91] recurrence within 180 days (bacteremic & non-bacteremic) in this subgroup 15/142 patients (10.6%) mono-therapy vs. 9/202 (4.5%) co-therapy (p=0.03) all butESCMID one without overt device infectioneLibraryin initial SAB ©Rieg, ClinbyMicrobiol Infectauthor2016 RCT in UK Adjunctive rifampicin in SAB 758 patients with MSSA/MRSA bacteremia randomized to either rifampicin 14d (600-900mg) vs. placebo Inclusion criteria: active antibiotic therapy ≤96h Primary endpoint: bacteriologically confirmed failure or death or recurrence within 12 weeks Patients included: age 65, Charlson score 2, com.-acquisition 64%, MRSAB 7% . 60% of patients with non deep-seated focus (iv-cath, SSTI, respiratory/urinary tract, unknown focus) . 40% of patients with deep-seated focus . 23% deep tissue abscess . 8% native joint ESCMID. 4% native / 2% prosthetic eLibraryheart valve . 5% implanted vascular device ©Late breaker bySession #OS0250Gauthor RCT in UK: Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST) Treatment duration 29 days, 85% antistaph. penicillin SAE comparable, more drug interaction & antibiotic modifying AEs in rifampicin group Prim. endpoint: failure/death or recurrence within 12w 62 events in rifampcin vs. 71 in placebo group (difference -1,4% [95% CI -7,1%; +4.2%]) HR 0,96 [95% CI 0,68-1,34], p=0.8 No signs of heterogeneity within 18 subgroups (p>0.05) ESCMID(enough patients in subgroups eLibrary of interest included?) ©Late breaker bySession #OS0250Gauthor RCT in UK: Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST) Endpoint recurrence bact. confirmed n=3 rifampicin vs. n=16 placebo (p=0.01) clin. confirmed n=8 rifampicin vs. n=22 placebo (p=0.01) NNT to prevent one recurrence = 29 (clin. conf. 26) Interpretation (so far) ‘uncompl.’ S. aureus bacteremia: no need for co-therapy focus superficial (iv-cath, SSTI), respirator and urogenital tract deep-seated manifestations/abscesses no final decision yet in specific subgroups implanted foreign bodies/devices ESCMIDnative/prosthetic valve endocarditis eLibrary © by author Thank you for your attention! Bildbereich Bitte auf der Masterfolie austauschen Siegbert Rieg Division of Infectious Diseases, Department of Medicine II & Center of Chronic Immunodeficiency (CCI) ESCMIDUniversity Medical eLibrary Center Freiburg, Germany © by author.
Load more

Recommended publications
  • Dabigatran Amoxicillin Clavulanate IV Treatment in the Community
    BEST PRACTICE 38 SEPTEMBER 2011 Dabigatran Amoxicillin clavulanate bpac nz IV treatment in the community better medicin e Editor-in-chief We would like to acknowledge the following people for Professor Murray Tilyard their guidance and expertise in developing this edition: Professor Carl Burgess, Wellington Editor Dr Gerry Devlin, Hamilton Rebecca Harris Dr John Fink, Christchurch Dr Lisa Houghton, Dunedin Programme Development Dr Rosemary Ikram, Christchurch Mark Caswell Dr Sisira Jayathissa, Wellington Rachael Clarke Kate Laidlow, Rotorua Peter Ellison Dr Hywel Lloyd, GP Reviewer, Dunedin Julie Knight Associate Professor Stewart Mann, Wellington Noni Richards Dr Richard Medlicott, Wellington Dr AnneMarie Tangney Dr Alan Panting, Nelson Dr Sharyn Willis Dr Helen Patterson, Dunedin Dave Woods David Rankin, Wellington Report Development Dr Ralph Stewart, Auckland Justine Broadley Dr Neil Whittaker, GP Reviewer, Nelson Tim Powell Dr Howard Wilson, Akaroa Design Michael Crawford Best Practice Journal (BPJ) ISSN 1177-5645 Web BPJ, Issue 38, September 2011 Gordon Smith BPJ is published and owned by bpacnz Ltd Management and Administration Level 8, 10 George Street, Dunedin, New Zealand. Jaala Baldwin Bpacnz Ltd is an independent organisation that promotes health Kaye Baldwin care interventions which meet patients’ needs and are evidence Tony Fraser based, cost effective and suitable for the New Zealand context. Kyla Letman We develop and distribute evidence based resources which describe, facilitate and help overcome the barriers to best Clinical Advisory Group practice. Clive Cannons nz Michele Cray Bpac Ltd is currently funded through contracts with PHARMAC and DHBNZ. Margaret Gibbs nz Dr Rosemary Ikram Bpac Ltd has five shareholders: Procare Health, South Link Health, General Practice NZ, the University of Otago and Pegasus Dr Cam Kyle Health.
    [Show full text]
  • Flucloxacillin Capsules in This Leaflet: 1 What Flucloxacillin Capsules Are
    Flucloxacillin capsules This information is a summary only. It does not contain all information about this medicine. If you would like more information about the medicine you are taking, check with your doctor or other health care provider. No rights can be derived from the information provided in this medicine leaflet. In this leaflet: If you take more than you should 1 What Flucloxacillin capsules are and what they are used for If you (or someone else) swallow a lot of capsules at the same time, or you think a 2 Before you take child may have swallowed any contact your nearest hospital casualty department 3 How to take or tell your doctor immediately. Symptoms of an overdose include feeling or 4 Possible side effects being sick and diarrhoea. 5 How to store If you forget to take the capsules 1 What Flucloxacillin capsules are and what they are used for Do not take a double dose to make up for a forgotten dose. If you forget to take a Flucloxacillin is an antibiotic used to treat infections by killing the bacteria that dose take it as soon as you remember it and carry on as before, try to wait about can cause them. It belongs to a group of antibiotics called “penicillins”. four hours before taking the next dose. Flucloxacillin capsules are used to treat: • chest infections If you stop taking the capsules • throat or nose infections Do not stop treatment early because some bacteria may survive and cause the • ear infections infection to come back. • skin and soft tissue infections • heart infections 4 Possible side effects • bones and joints infections Like all medicines, Flucloxacillin capsules can cause side effects, although not • meningitis everybody gets them.
    [Show full text]
  • Clinical Management of Staphylococcus Aureus Bacteremia in Neonates, Children, and Adolescents
    Clinical Management of Staphylococcus aureus Bacteremia in Neonates, Children, and Adolescents Brendan J. McMullan, BMed (Hons), FRACP, FRCPA,a,b,c,* Anita J. Campbell, MBBS, DCH, DipPID, FRACP,d,e,f,* Christopher C. Blyth, MBBS (Hons), PhD, DCH, FRACP, FRCPA,d,e,f,g J. Chase McNeil, BS, MD,h Christopher P. Montgomery, BA, MD,i,j Steven Y.C. Tong, MBBS (Hons), PhD, FRACP,k,l Asha C. Bowen, BA, MBBS, PhD, FRACPd,e,f,k,m Staphylococcus aureus is a common cause of community and health abstract – care associated bacteremia, with authors of recent studies estimating the aDepartment of Immunology and Infectious Diseases, incidence of S aureus bacteremia (SAB) in high-income countries between 8 Sydney Children’s Hospital, Randwick, New South Wales, , Australia; bSchool of Women’s and Children’s Health, and 26 per 100 000 children per year. Despite this, 300 children worldwide University of New South Wales, Sydney, New South Wales, have ever been randomly assigned into clinical trials to assess the efficacy Australia; cNational Centre for Infections in Cancer, of treatment of SAB. A panel of infectious diseases physicians with clinical University of Melbourne, Melbourne, Victoria, Australia; dDepartment of Infectious Diseases, Perth Children’s and research interests in pediatric SAB identified 7 key clinical questions. Hospital, Nedlands, Western Australia, Australia; The available literature is systematically appraised, summarizing SAB eWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, Western Australia,
    [Show full text]
  • Australian Public Assessment Refport for Ceftaroline Fosamil (Zinforo)
    Australian Public Assessment Report for ceftaroline fosamil Proprietary Product Name: Zinforo Sponsor: AstraZeneca Pty Ltd May 2013 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) • The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health and Ageing, and is responsible for regulating medicines and medical devices. • The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. • The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. • The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. • To report a problem with a medicine or medical device, please see the information on the TGA website <http://www.tga.gov.au>. About AusPARs • An Australian Public Assessment Record (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. • AusPARs are prepared and published by the TGA. • An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations, and extensions of indications. • An AusPAR is a static document, in that it will provide information that relates to a submission at a particular point in time. • A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA.
    [Show full text]
  • Flucloxacillin 500Mg Capsules BP (Flucloxacillin Sodium)
    PACKAGE LEAFLET: INFORMATION FOR THE USER Flucloxacillin 250mg Capsules BP Flucloxacillin 500mg Capsules BP (flucloxacillin sodium) Read all of this leaflet carefully before you start taking Warnings and precautions this medicine because it contains important information Talk to your doctor or pharmacist before taking this medicine if for you. you: - Keep this leaflet. You may need to read it again. • are 50 years of age or older - If you have any further questions, ask your doctor, • have other serious illness (apart from the infection this pharmacist or nurse. medicine is treating). - This medicine has been prescribed for you only. Do not • suffer from kidney problems, as you may require a lower pass it on to others. It may harm them, even if their signs dose than normal (convulsions may occur very rarely in of illness are the same as yours. patients with kidney problems who take high doses). - If you get any side effects, talk to your doctor or • suffer from liver problems, as this medicine could cause pharmacist. This includes any possible side effects not them to worsen. listed in this leaflet. See section 4. • are taking this medicine for a long time as regular tests of liver and kidney function are advised What is in this leaflet • are taking or will be taking paracetamol 1. What Flucloxacillin Capsules are and what they are used • are on a sodium-restricted diet. for • are giving this medicine to a newborn child 2. What you need to know before you take Flucolxacillin Capsules The use of flucloxacillin, especially in high doses, may reduce 3.
    [Show full text]
  • Impetigo: Antimicrobial Prescribing
    DRAFT FOR CONSULTATION 1 Impetigo: antimicrobial prescribing 2 NICE guideline 3 Draft for consultation, August 2019 This guideline sets out an antimicrobial prescribing strategy for impetigo. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations in this guideline are for the use of antiseptics and antibiotics to manage impetigo in adults, young people and children. It does not cover diagnosis. Please note that the scope of this guideline is for adults, young people and children aged 72 hours and over. For treatment of children in the first 72 hours of life, please seek specialist advice. For managing other skin infections, see our web page on skin conditions. See a 2-page visual summary of the recommendations, including tables to support prescribing decisions. Who is it for? • Healthcare professionals • Adults, young people and children with impetigo, their parents and carers The guideline contains: • the draft recommendations • the rationales • summary of the evidence. Information about how the guideline was developed is on the guideline’s page on the NICE website. This includes the full evidence review, details of the committee and any declarations of interest. Impetigo: antimicrobial prescribing guidance DRAFT (August 2019) Page 1 of 20 DRAFT FOR CONSULTATION 1 Recommendations 2 1.1 Managing impetigo 3 Advice to reduce the spread of impetigo 4 1.1.1 Advise adults, young people and children, and their parents or 5 carers if appropriate, about good hygiene measures to reduce the 6 spread of impetigo to other areas of the body and to other people. To find out why the committee made the recommendations on advice to reduce the spread of impetigo see the rationales.
    [Show full text]
  • Use of Ceftaroline in Hospitalized Patients with and Without COVID-19: a Descriptive Cross-Sectional Study
    antibiotics Article Use of Ceftaroline in Hospitalized Patients with and without COVID-19: A Descriptive Cross-Sectional Study Daniele Roberto Giacobbe 1,2,*, Chiara Russo 1,2, Veronica Martini 3, Silvia Dettori 1,2, Federica Briano 1,2, Michele Mirabella 2, Federica Portunato 2, Chiara Dentone 2, Sara Mora 4, Mauro Giacomini 4 , Marco Berruti 1,2 and Matteo Bassetti 1,2 1 Department of Health Sciences, University of Genoa, 16132 Genoa, Italy; [email protected] (C.R.); [email protected] (S.D.); [email protected] (F.B.); [email protected] (M.B.); [email protected] (M.B.) 2 Clinica Malattie Infettive, San Martino Policlinico Hospital—IRCCS, 16132 Genoa, Italy; [email protected] (M.M.); [email protected] (F.P.); [email protected] (C.D.) 3 School of Medicine, University of Genoa, 16132 Genoa, Italy; [email protected] 4 Department of Informatics Bioengineering, Robotics, and Systems Engineering (DIBRIS), University of Genoa, 16145 Genoa, Italy; [email protected] (S.M.); [email protected] (M.G.) * Correspondence: [email protected] Abstract: A single-center cross-sectional study was conducted to describe the use of ceftaroline in a large teaching hospital in Northern Italy, during a period also including the first months of the coronavirus disease 2019 (COVID-19) pandemic. The primary objective was to describe the use of ceftaroline in terms of indications and characteristics of patients. A secondary objective was to Citation: Giacobbe, D.R.; Russo, C.; describe the rate of favorable clinical response in patients with bloodstream infections (BSI) due to Martini, V.; Dettori, S.; Briano, F.; methicillin-resistant Staphylococcus aureus (MRSA-BSI) receiving ceftaroline.
    [Show full text]
  • APO-Flucloxacillin Flucloxacillin Sodium Consumer Medicine Information
    APO-Flucloxacillin Flucloxacillin sodium Consumer Medicine Information For a copy of a large print leaflet, Ph: 1800 195 055 What is in this leaflet Your doctor may have prescribed this liver while you were taking medicine for another reason. flucloxacillin or another penicillin This leaflet answers some common This medicine is available only with antibiotic. questions about flucloxacillin. It does a doctor©s prescription. Examples of liver reactions include not contain all the available This medicine is not addictive. hepatitis and jaundice (yellowing of information. It does not take the the eyes or skin). There is not enough information to place of talking to your doctor or Do not take this medicine after the pharmacist. recommend the use of this medicine for children under the age of 2 years expiry date printed on the pack or All medicines have risks. Your if the packaging is torn or shows doctor has weighed the risks of you signs of tampering. using this medicine against the Do not use this medicine in your benefits they expect it will have for Before you take this eyes. you. medicine If it has expired or is damaged, return If you have any concerns about it to your pharmacist for disposal. taking this medicine, ask your WARNING: Flucloxacillin can If you are not sure whether you doctor or pharmacist. cause severe liver damage, should start taking this medicine, particularly in older patients and Keep this leaflet with the medicine. talk to your doctor. those who take it for more than 14 You may want to read it again.
    [Show full text]
  • Flucloxacillin Alone Or Combined with Benzylpenicillin to Treat Lower Limb Cellulitis: a Randomised Controlled Trial P Leman, D Mukherjee
    342 ORIGINAL ARTICLE Emerg Med J: first published as 10.1136/emj.2004.019869 on 20 April 2005. Downloaded from Flucloxacillin alone or combined with benzylpenicillin to treat lower limb cellulitis: a randomised controlled trial P Leman, D Mukherjee ............................................................................................................................... Emerg Med J 2005;22:342–346. doi: 10.1136/emj.2004.019869 Objective: To determine whether using intravenous benzylpenicillin in addition to intravenous flucloxacillin would result in a more rapid clinical response in patients with lower limb cellulitis. Methods: This was a randomised controlled trial set in an inner city teaching hospital, comprising 81 patients with lower limb cellulitis requiring intravenous antibiotics. The main outcome measure was the mean number of doses of antibiotic required until clinical response. See end of article for Results: The mean number of doses required was 8.47 (95% confidence interval (CI) 7.09 to 9.86) in the authors’ affiliations benzylpenicillin and flucloxacillin combined group. In the flucloxacillin only group it was 8.71 doses (95% ....................... CI 6.90 to 10.5), a mean difference of 20.24 doses (95% CI 22.48 to 2.01, p = 0.83). Other markers of Correspondence to: treatment efficacy showed no difference between groups at review the following day; temperature Dr P Leman, Emergency decrease (mean difference 20.07˚C, 95% CI 20.76 to 0.62, p = 0.84), or diameter decrease of affected Department, Royal Perth area (mean difference 234 mm, 95% CI 299 to 31, p = 0.30). Patient subjective assessments were also Hospital, Wellington Street, Perth, WA 6001, similar between the different drug regimen; improvement on a visual analogue scale of pain/discomfort Australia; peter.leman@ from admission to first review (mean difference 10 mm, 95% CI 212.6 to 14.2, p = 0.91) and on second health.wa.gov.au review (mean difference 15 mm, 95% CI 218.6 to 21.6, p = 0.88).
    [Show full text]
  • Support in Choosing the Correct Antibiotic in Primary Care
    Support in choosing the correct antibiotic in Primary Care Antibiotic Sensitivity Chart Adapted from chart created by McCormack J and Lalji F, December 2015. Bacteria Antibiotic Gram Positive Cocci Gram Negative Bacilli Gram Negative Coccobacilli Anaerobes Neither Gram-positive or Gram-negative (Atypicals) Streptococci Staphylococci Streptococc Enterococci Staph Staph aureus Community Eschericha coli, Klebsiella SPACE ESBL (Extended Pseudomon Neisseria Neisseria Above the Below the Clostridium Mycoplasm Legionella Chlamydia i (Group D epidermidis Methicillin acquired pneumoniae, Haemophilus Serratia marcescens, spectrum beta- as meningitidis gonorrhoea diaphragm diaphragm difficile a pneumophil trachomatis (pneumoni strep) (coagulase sensitive Methicillin influenzae Proteus mirabilis, lactamase aeruginosa (Peptostrep (Bacteroides pneumonia ia ae/ negative) resistant Acinetobacter sp., producing tococcus) sp) e, pyogenes/ Citrobacter sp., Escherichia coli, Chlamydop viridins) Enterobacter sp. Klebsiella hilia spp pneumoniae) Location Brain, oral, Intraabdom Skin, Oral, respiratory tract, heart, Brain, respiratory tract, intraabdominal, urinary tract, e.g. UTI Brain Pelvic Oral, Intraabdominal Intraabdom Respiratory tract Pelvic respiratory inal, urinary prosthetics skin, bones/ joint inflammato respiratory , pelvic inal Inflammato tract, heart, tract, e.g. ry disease/ tract inflammatory ry disease/ skin, e.g. UTI STI disease STI cellulitis Penicillins Penicillin V Not Not effective Not effective Not Not effective Not effective Not effective
    [Show full text]
  • Antibiotic Impregnated Cotton Gauzes for Topical Antibiotic Treatment
    International Journal of Scientific & Engineering Research, Volume 7, Issue 7, July-2016 ISSN 2229-5518 266 ANTIBIOTIC IMPREGNATED COTTON GAUZES FOR TOPICAL ANTIBIOTIC TREATMENT J.G.B. Epakande, R.M.G. Rajapakse, R.B.S.D. Rajapakshe, C.A. Thennakoon, Sanath Rajapakse ABSTRACT-Antibiotics are powerful medicines that are used either to inhibit bacterial growth or to destroy bacteria. There are eight different types of antibiotics and the most suitable antibiotic for a particular disease is prescribed by a clinician. Overuse of antibiotics may cause severe problems such as side effects and development of resistance to such an antibiotic by the respective bacteria. Such an antimicrobial resistance is a potent issue worldwide since it demands the termination of the antibiotic and research into discovering new ones. Bioavailability of different types of antibiotics is different and is a critical factor determining the dose. Usual administrative methods such as oral administration or intravenous administration require high doses depending upon the bioavailability of a given antibiotic. As such, topical antibiotic treatment is getting attention of the researchers and is most suited for treating skin diseases and wounds. In this research, we have chosen four different antibiotics, namely, Cefuroxime, Azithromycin, Metronidazole and Flucloxacillin and 20 mg each of these drugs were dissolved, separately, in 20 mL of ethanol and the antibiotics were separately adsorbed to sterilized cotton gauzes and stored in sterilized plastic bottles closed with lids. Their antimicrobial efficacies on Gram-negative Escherichia coli and Gram-positive Staphylococcus aureus were studied after one week of gauze preparation. Another set was aged under ambient conditions, in plastic bottles closed with lids, and their antimicrobial efficacies were also investigated.
    [Show full text]
  • PACKAGE LEAFLET: INFORMATION for the USER Flucloxacillin
    PACKAGE LEAFLET: INFORMATION FOR THE USER Flucloxacillin 250mg, 500mg or 1g, Powder for Solution for Injection or Infusion Flucloxacillin as Flucloxacillin Sodium Read all of this leaflet carefully before you start using this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or nurse. • If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet: 1. What Flucloxacillin is and what it is used for 2. What you need to know before you are given Flucloxacillin Injection 3. How Flucloxacillin Injection is given 4. Possible side effects 5. How to store Flucloxacillin Injection 6. Contents of the pack and other information The name of your medicine is “Flucloxacillin 250mg, 500mg, 1g Powder for Solution for Injection or Infusion” (referred to as Flucloxacillin Injection throughout this leaflet). 1. WHAT FLUCLOXACILLIN IS AND WHAT IT IS USED FOR Your medicine contains the active substance flucloxacillin (as flucloxacillin sodium), which is one of a group of medicines called “penicillins”. These medicines are also known as “antibiotics” and they work by killing the bacteria that cause infections. Flucloxacillin injection is used to treat a wide range of bacterial infections which may include those affecting: • The chest (pneumonia, emphysema and lung abscess) • Tonsils (tonsillitis, quinsy) • Pharynx (pharyngitis) • Sinuses (sinusitis) • Ears (otitis media and otitis externa) • Skin and soft tissue (boils, abscesses, carbuncles, impetigo, cellulites, furunculosis, ulcers and acne) • Wounds and burns • Heart (endocarditis) • Bones and joints (osteomyelitis) • Membranes of the brain (meningitis) • Gut (enteritis) • Blood (Septicaemia) • Kidney, bladder or the urethra (the tube which carries urine from the bladder).
    [Show full text]